Key Points
- Director Matthew Posard sold 18,996 Halozyme shares for approximately $2.05 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 24.4% to 58,839 shares.
- Halozyme reported strong quarterly results, with revenue up 47.7% year over year to $481 million and EPS of $2.28, beating analysts’ $1.79 estimate. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
- Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating, while the proposed $1.05 billion convertible-notes offering could increase leverage and create potential dilution for shareholders.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Matthew Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares of the company's stock, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Halozyme Therapeutics Stock Up 1.1%
HALO opened at $109.68 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $111.15. The business has a 50-day moving average of $95.95 and a two-hundred day moving average of $78.09. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a market capitalization of $12.45 billion, a price-to-earnings ratio of 32.74, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 EPS. The company's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.
Key Halozyme Therapeutics News
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Recent investor commentary highlighted Halozyme’s attractive growth profile, supported by its drug-delivery technology platform, recurring royalty revenue and strong earnings outlook. The company’s latest reported quarter also exceeded expectations, with revenue rising 47.7% year over year and EPS surpassing consensus estimates. Three Reasons Why Growth Investors Shouldn't Overlook Halozyme
- Neutral Sentiment: Halozyme’s presentation at the H.C. Wainwright investment conference kept attention focused on its growth strategy and pipeline, although no clearly market-moving new guidance was reported. Halozyme H.C. Wainwright Conference Presentation
- Negative Sentiment: Halozyme announced a proposed private offering of $1.05 billion of convertible senior notes due 2033. The financing could provide substantial capital on potentially favorable terms, but it also increases leverage and may dilute existing shareholders if the notes are converted, creating an overhang for the stock. Final terms remain subject to market conditions. Halozyme Announces Proposed Convertible Notes Offering
- Negative Sentiment: Director Matthew Posard sold 18,996 shares worth approximately $2.05 million, reducing his position by 24.4%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but insider selling can still weigh modestly on sentiment. Halozyme Director Stock Sale SEC Filing
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on HALO shares. Citizens Jmp lifted their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a report on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, August 31st. Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $115.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Finally, Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $91.20.
Get Our Latest Stock Analysis on Halozyme Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Talon Private Wealth LLC purchased a new stake in Halozyme Therapeutics during the second quarter worth approximately $839,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth $359,000. Tidal Investments LLC raised its stake in shares of Halozyme Therapeutics by 13.5% in the 2nd quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company's stock valued at $14,895,000 after acquiring an additional 22,707 shares during the period. WINTON GROUP Ltd raised its stake in shares of Halozyme Therapeutics by 704.6% in the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company's stock valued at $4,723,000 after acquiring an additional 52,848 shares during the period. Finally, Engineers Gate Manager LP lifted its holdings in shares of Halozyme Therapeutics by 6.7% during the 2nd quarter. Engineers Gate Manager LP now owns 46,172 shares of the biopharmaceutical company's stock valued at $3,614,000 after acquiring an additional 2,889 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.
Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
